Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1022

Recombinant VP4 Polypeptides as Antigens for a Rotavirus Vaccine

Inventors: Stephen Harrison, Philip Dormitzer, Joshua Yoder, Harry Greenberg

Invention Types: Therapeutics

Research Areas: Gastrointestinal/Nutrition

Keywords: Vaccine

For More Information Contact:  Caron, Connie

 

Invention Description:

The invention provides a novel structure-based approach for the design of specific, safe and stable vaccine against rotavirus infections. The invention is based on the high-resolution structural data of fragments of the rotavirus neutralizing antigen VP4 and the specific engineering of these polypeptides, or the nucleic acids that encode them, into the vaccines.

Applications:

The invention has applications in the treatment of the most common cause of severe vomiting and diarrhea in children worldwide. The methods and polypeptides presented in this invention could be applied in the diagnosis, treatment and prevention of rotavirus infections. Recombinant VP4 polypeptides can be used as antigens for vaccine development.

Competitive Advantages:

The structure-based molecular engineering approach has major advantages over other techniques of vaccine design used today. These include safety, high degree of specificity, proper conformation of epitopes and inexpensive generation of inherently non-infectious and gut-stable molecules. The invention provides a variety of molecules such as recombinant polypeptides and their fusions, fragments, variants and derivatives.

Business Opportunity:

Children's hospital is looking to license this technology for development.

Key Publications: J Virol. 2001 Aug;75(16):7339-50

IPStatus: Pat. Pend.